Metastatic Breast Cancer Clinical Trials

205 recruitingLast updated: June 17, 2026

There are 205 actively recruiting metastatic breast cancer clinical trials across 54 countries. Studies span Phase 2, Phase 1, Phase 3, Not Applicable, Phase 4, Early Phase 1. Top locations include Boston, Massachusetts, United States, New York, New York, United States, Houston, Texas, United States. Updated daily from ClinicalTrials.gov.


Metastatic Breast Cancer Trials at a Glance

205 actively recruiting trials for metastatic breast cancer are listed on ClinicalTrialsFinder across 6 cities in 54 countries. The largest study group is Phase 2 with 80 trials, with the heaviest enrollment activity in Boston, New York, and Houston. Lead sponsors running metastatic breast cancer studies include Memorial Sloan Kettering Cancer Center, Fudan University, and Shandong Suncadia Medicine Co., Ltd..

Browse metastatic breast cancer trials by phase

Treatments under study

About Metastatic Breast Cancer Clinical Trials

Looking for clinical trials for Metastatic Breast Cancer? There are currently 155 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Metastatic Breast Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Metastatic Breast Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 205 trials

Recruiting
Phase 3

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

Breast CancerMetastatic Breast CancerHER2-Negative Breast Carcinoma+2 more
Olema Pharmaceuticals, Inc.1,000 enrolled150 locationsNCT07085767
Recruiting

A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer

Metastatic Breast CancerLocally Advanced Breast Cancer
Hoffmann-La Roche500 enrolled23 locationsNCT07347600
Recruiting
Phase 2

PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)

Breast CancerMetastatic Breast CancerBreast Neoplasms+6 more
Kristina A. Fanucci297 enrolled1 locationNCT07222215
Recruiting
Phase 3

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

Breast CancerMetastatic Breast CancerHER2-negative Breast Cancer+3 more
Relay Therapeutics, Inc.540 enrolled192 locationsNCT06982521
Recruiting
Not Applicable

The Efficacy of Compression/Ice Gloves/Socks in Patients With UTD1-induced Neuropathy.

Locally Advanced or Metastatic Breast Cancer
Fudan University324 enrolled1 locationNCT07638774
Recruiting
Phase 1Phase 2

ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer

Breast CancerMetastatic Breast CancerBreast Cancer Female+2 more
Kristina A. Fanucci65 enrolled1 locationNCT07198724
Recruiting
Early Phase 1

First-in-human Diagnostic Imaging Profile of the Theranostic Pair [68Ga]Ga-DOTA-STR-17126 and Low Dose [177Lu] Lu-DOTA-STR-17126 in Patients With Advanced or Metastatic Cancer

Metastatic Breast CancerCancerMetastatic Prostate Cancer+5 more
Integrated Haematology and Oncology Network20 enrolled1 locationNCT07608848
Recruiting
Phase 2

Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)

Metastatic Breast CancerHER2-negative Breast CancerMetaplastic Breast Carcinoma+1 more
The Methodist Hospital Research Institute36 enrolled3 locationsNCT05660083
Recruiting
Phase 1

BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer

Metastatic Breast CancerHER2-negative Breast CancerHormone Receptor-Positive Breast Cancer
BeOne Medicines120 enrolled15 locationsNCT06756932
Recruiting
Phase 3

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

Metastatic Breast Cancer
American Society of Clinical Oncology500 enrolled73 locationsNCT06377852
Recruiting
Phase 3

A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy.

Locally Advanced or Metastatic Breast Cancer
Shandong Suncadia Medicine Co., Ltd.912 enrolled1 locationNCT07354022
Recruiting
Phase 2

HER2 Targeted Molecular Imaging in mBC and Other Metastatic Solid Carcinomas Using 68Ga-ABS011

Metastatic Breast CancerMetastatic Solid Cancer
Abscint NV/SA60 enrolled7 locationsNCT06369831
Recruiting
Phase 1

A Study of HLD-0117 in Patients With Metastatic Breast Cancer

Metastatic Breast Cancer
Halda Therapeutics OpCo, Inc.33 enrolled4 locationsNCT07524855
Recruiting
Phase 2

Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease

Metastatic Breast Cancer in the Liver
Delcath Systems Inc.90 enrolled5 locationsNCT06875128
Recruiting
Phase 2

Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis

Metastatic Breast CancerLeptomeningeal Disease
Wake Forest University Health Sciences16 enrolled3 locationsNCT02422641
Recruiting

DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients

Metastatic Breast CancerHER2-Negative Breast CarcinomaHER2-negative Breast Cancer+6 more
Mayo Clinic100 enrolled1 locationNCT06388122
Recruiting

Minimally Interventional Study on Prevalence of Emerging ESR1 Mutations in Liquid Biopsy in Three Cohorts of Patients With Breast Cancer in Comparison With Patient's Baseline ESR1 Mutation Status as Defined by Tissue Profiling.

Metastatic Breast Cancer
AstraZeneca170 enrolled6 locationsNCT06417801
Recruiting
Phase 1

A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors

Metastatic Breast CancerAdvanced Solid TumorMetastatic Ovarian Cancer+3 more
EtiraRx Australia Pty Ltd36 enrolled5 locationsNCT06533332
Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

Metastatic Breast Cancer
Hoffmann-La Roche230 enrolled192 locationsNCT05894239
Recruiting
Phase 1

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

Metastatic Breast CancerHER2-negative Breast CancerAdvanced Solid Tumor+6 more
BeOne Medicines399 enrolled63 locationsNCT06120283